Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Friday, July 31, 2026.
Reported quarterly gross margin; no daily interpolation. Q3 FY2026 (2026-07-31): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
39.56%
median of 699 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
enGene Holdings Inc.
Market Cap
$122.93M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$122.89M
Gross Margin
-62.76%
TTM Avg
-61.84%
3Y Avg
-230.63%
5Y Avg
-163.28%
Market Cap
$121.00M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$125.34M
Gross Margin
58.78%
TTM Avg
29.39%
3Y Avg
14.70%
5Y Avg
9.80%
Market Cap
$118.89M
Gross Margin
90.14%
TTM Avg
48.16%
3Y Avg
49.08%
5Y Avg
32.72%
Market Cap
$117.53M
Gross Margin
67.34%
TTM Avg
64.03%
3Y Avg
72.89%
5Y Avg
33.80%
Market Cap
$116.57M
Gross Margin
11.17%
TTM Avg
22.02%
3Y Avg
17.41%
5Y Avg
13.61%
Market Cap
$116.81M
Gross Margin
-7075.00%
TTM Avg
-9131.25%
3Y Avg
-4667.52%
5Y Avg
-3111.68%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| enGene Holdings Inc. (ENGN) | $122.93M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cibus, Inc. (CBUS)vs › | $122.89M | -62.76% | -61.84% | -230.63% | -163.28% |
| TuHURA Biosciences, Inc. (HURA)vs › | $121.00M | 0.00% | 0.00% | 0.00% | 0.00% |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $125.34M | 58.78% | 29.39% | 14.70% | 9.80% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.89M | 90.14% | 48.16% | 49.08% | 32.72% |
| Entera Bio Ltd. (ENTX)vs › | $127.66M | 0.00% | 2.48% | -4.54% | 5.72% |
| Caribou Biosciences, Inc. (CRBU)vs › | $117.53M | 67.34% | 64.03% | 72.89% | 33.80% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $116.57M | 11.17% | 22.02% | 17.41% | 13.61% |
| Genelux Corporation (GNLX)vs › | $116.81M | -7075.00% | -9131.25% | -4667.52% | -3111.68% |
| Coya Therapeutics, Inc. (COYA)vs › | $116.34M | 99.91% | -67.10% | -31.47% | -20.98% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-07-31 | 0.00% |
| 2026-04-30 | 0.00% |
| 2026-01-31 | 0.00% |
| 2025-10-31 | 0.00% |
| 2025-07-31 | 0.00% |
| 2025-04-30 | 0.00% |
| 2025-01-31 | 0.00% |
| 2024-10-31 | 0.00% |
| 2024-07-31 | 0.00% |
| 2024-04-30 | 0.00% |
| 2024-01-31 | 0.00% |
| 2023-10-31 | 0.00% |
| 2023-07-31 | 0.00% |
| 2023-04-30 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-10-31 | 0.00% |
| 2022-07-31 | 0.00% |
| 2022-04-30 | 0.00% |
| 2021-12-31 | 0.00% |
